ATE444488T1 - Non-apoptotische formen des zelltods und verfahren zur modulation - Google Patents

Non-apoptotische formen des zelltods und verfahren zur modulation

Info

Publication number
ATE444488T1
ATE444488T1 AT01997059T AT01997059T ATE444488T1 AT E444488 T1 ATE444488 T1 AT E444488T1 AT 01997059 T AT01997059 T AT 01997059T AT 01997059 T AT01997059 T AT 01997059T AT E444488 T1 ATE444488 T1 AT E444488T1
Authority
AT
Austria
Prior art keywords
paraptosis
cell death
methods
modulation
caspase
Prior art date
Application number
AT01997059T
Other languages
English (en)
Inventor
Sabina Sperandio
Belle Ian De
Dale Bredesen
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Application granted granted Critical
Publication of ATE444488T1 publication Critical patent/ATE444488T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
AT01997059T 2000-12-14 2001-12-13 Non-apoptotische formen des zelltods und verfahren zur modulation ATE444488T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25602300P 2000-12-14 2000-12-14
US25669400P 2000-12-19 2000-12-19
PCT/US2001/048261 WO2002054066A2 (en) 2000-12-14 2001-12-13 Non-apoptotic forms of cell death and methods of modulation

Publications (1)

Publication Number Publication Date
ATE444488T1 true ATE444488T1 (de) 2009-10-15

Family

ID=26945108

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01997059T ATE444488T1 (de) 2000-12-14 2001-12-13 Non-apoptotische formen des zelltods und verfahren zur modulation

Country Status (6)

Country Link
US (1) US20090263852A1 (de)
EP (1) EP1342085B1 (de)
AT (1) ATE444488T1 (de)
AU (1) AU2002248180A1 (de)
DE (1) DE60140074D1 (de)
WO (1) WO2002054066A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04011624A (es) 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
FI20030130A0 (fi) 2003-01-29 2003-01-29 Licentia Oy Seulontamenetelmä
EP1694850B1 (de) 2003-11-12 2011-06-29 Schering Corporation Plasmidsystem zur expression mehrerer gene
EP2281841A3 (de) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomarker zur Vorauswahl von Patienten für eine Anti-IGF1R Therapie
WO2007139961A1 (en) * 2006-05-25 2007-12-06 The University Of Chicago Methods of reducing cell death following hypoxia / reoxygenation
US9089520B2 (en) 2010-05-21 2015-07-28 Baylor College Of Medicine Methods for inducing selective apoptosis
US9434935B2 (en) 2013-03-10 2016-09-06 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof
EP3569253A1 (de) 2013-06-05 2019-11-20 Bellicum Pharmaceuticals, Inc. Verfahren zur induktion von partieller apoptose mithilfe von caspasepolypeptiden
EP3076962A4 (de) * 2013-12-02 2017-10-18 The Trustees of Columbia University in the City of New York Modulation von ferroptose und behandlung von exzitotoxischen störungen
EP3114217A4 (de) * 2014-03-07 2017-09-20 Bellicum Pharmaceuticals, Inc. Caspasepolypeptide mit modifizierter aktivität und verwendungen davon
WO2016071758A1 (en) 2014-11-03 2016-05-12 Leiden University Medical Center T cell receptors directed against bob1 and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63218681A (ja) * 1987-03-09 1988-09-12 Mitsubishi Kasei Corp オリゴマイシンｅ
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5958872A (en) * 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
US5752515A (en) * 1996-08-21 1998-05-19 Brigham & Women's Hospital Methods and apparatus for image-guided ultrasound delivery of compounds through the blood-brain barrier
US6063758A (en) * 1997-07-09 2000-05-16 Advanced Targeting Systems, Inc. Substance P-Saporin (SP-SAP) conjugates and methods of use thereof
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
US20040072888A1 (en) * 1999-08-19 2004-04-15 Bennett Brydon L. Methods for treating inflammatory conditions or inhibiting JNK
US7119114B1 (en) * 1999-08-19 2006-10-10 Signal Pharmaceuticals, Llc Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related thereto
US7018988B2 (en) * 2000-03-27 2006-03-28 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
WO2003032981A1 (en) * 2001-10-16 2003-04-24 Memory Pharmaceuticals Corporation 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
US6994981B2 (en) * 2002-02-19 2006-02-07 The Buck Institute Modulators of paraptosis and related methods

Also Published As

Publication number Publication date
EP1342085A2 (de) 2003-09-10
AU2002248180A1 (en) 2002-07-16
DE60140074D1 (de) 2009-11-12
WO2002054066A2 (en) 2002-07-11
US20090263852A1 (en) 2009-10-22
EP1342085B1 (de) 2009-09-30
WO2002054066A3 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
MX9801093A (es) Inhibidores de la proteinasa c para el tratamiento de enfermedades relacionadas con la sobreproduccion de colagena.
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
ATE333888T1 (de) Verwendung eines polypeptids, welches die extrazelluläre domäne von il-20ra und il-20rb enthält, zur behandlung von entzündungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE519862T1 (de) Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE60140074D1 (de) Non-apoptotische formen des zelltods und verfahren zur modulation
ATE454161T1 (de) Verwendung von fviia oder fviiai zur behandlung von endothelialer fehlfunktion bzw zur inhibierung der angiogenese
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE538781T1 (de) Neue verwendung von peptidverbindungen zur behandlung von dyskinesie
ATE461697T1 (de) Phospholipidderivate von valproinsäure und ihre kombinationen
ATE393775T1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
ATE394124T1 (de) Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
NO20010389D0 (no) Modulering av multippel linje-kinaseproteiner
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE288498T1 (de) Methoden zur inhibierung von helicobacter pylori
ATE339208T1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties